---
schema_version: "secwatch.filing_event.v1"
accession: "0001581280-26-000016"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:36:17.687458+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q1 FY26: Record revenue $103.7M (+17% YoY), raises FY guidance to $435-440M

## Summary
- Revenue $103.7M (+17% YoY), 12th consecutive sequential growth; exceeded guidance.
- Gross margin 52.0% (+4 pts YoY); net loss narrowed to $30.5M ($0.50/share) vs $31.6M.
- DNA Synthesis & Protein Solutions rev $51.1M (+27% YoY); NGS Apps $52.6M (+8%, ex-large customer +18%).
- FY2026 revenue guidance raised to $435-440M; reaffirms Q4 Adj EBITDA breakeven on track.
- Cash $198M; shipped to ~2,538 customers, ~271,000 genes; launched research-grade plasmid DNA preps.

## SEC filing metadata
- accession: 0001581280-26-000016
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000016/0001581280-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000016/twist-20260202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001581280-26-000016
- JSON: https://secwatch.observer/filing/0001581280-26-000016.json
- Plain text: https://secwatch.observer/filing/0001581280-26-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.